About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Leukemia Clinical Trials in Austin | 1,273 Studies | Clareo Health

Clinical Trials LeukemiaAustin

Leukemia Clinical Trials in Austin

Find 1,273 clinical trials for leukemia near Austin, Texas. Connect with research centers in your area.

All Leukemia trials nationwide All trials in Austin

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 1101-1120 of 1,273 trials

COMPLETEDPhase 3< 1 mile

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

NCT00790023

To demonstrate the efficacy of ciclesonide HFA applied as a nasal aerosol (160 μg and 80 μg) once daily compared to placebo in subjects with SAR.

Seasonal Allergic Rhinitis

Sumitomo Pharma America, Inc.707 participantsStarted Nov 2008

Austin, Texas, United States • Kerrville, Texas, United States • New Braunfels, Texas, United States +1 more locations

TERMINATEDPhase 217 miles

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

NCT00595920

The purpose of this study is to further evaluate the safety and efficacy of Tovaxin in the treatment of relapsing forms of multiple sclerosis.

Multiple Sclerosis, Relapsing-RemittingClinically Isolated Syndrome

Opexa Therapeutics, Inc.116 participantsStarted Nov 2007

Cullman, Alabama, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +24 more locations

Leukemia Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

COMPLETEDPhase 317 miles

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

NCT01355484

The purpose of this study is to determine if the investigational drug GTx-024 can help subjects with non-small cell lung cancer increase physical function and maintain or gain muscle, also called "lean body mass".

Muscle WastingNon Small Cell Lung Cancer

GTx321 participantsStarted Jul 2011

Birmingham, Alabama, United States • Long Beach, California, United States • Aventura, Florida, United States +24 more locations

COMPLETEDPhase 262 miles

Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

NCT01137968

The purpose of this is to evaluate the efficacy and safety of imetelstat (GRN163L) as maintenance therapy for patients with advanced stage NSCLC who have not progressed after 4 cycles of platinum based therapy. Participants will be randomized in a 2:1 ratio to imetelstat + standard of care versus standard of care alone. Participants who received bevacizumab with their induction chemotherapy will continue to receive bevacizumab on this study.

Non-small Cell Lung Cancer

Geron Corporation116 participantsStarted May 2010

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Anaheim, California, United States +30 more locations

COMPLETEDNA74 miles

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

NCT00080873

RATIONALE: Traumeel® S (a mouth rinse) may be effective in preventing or decreasing the severity of oral mucositis caused by chemotherapy in young patients who are undergoing stem cell transplantation. PURPOSE: This randomized clinical trial is studying how well Traumeel® S works in preventing or treating mucositis in young patients who are receiving chemotherapy with or without total-body irradiation before undergoing stem cell transplantation.

Kidney CancerLeukemiaLymphoma+3 more

Children's Oncology Group195 participantsStarted Apr 2004

Birmingham, Alabama, United States • Los Angeles, California, United States • Orange, California, United States +41 more locations

COMPLETEDPhase 374 miles

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

NCT00409188

The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung cancer, compared to best supportive care alone. A local ancillary (sub) study in European centers will evaluate the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination.

Non-small Cell Lung Cancer

EMD Serono1,513 participantsStarted Jan 2007

Fort Smith, Arkansas, United States • Anaheim, California, United States • Glendale, California, United States +287 more locations

COMPLETEDPhase 1147 miles

Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

NCT01398462

CWP232291 blocks proliferation of cancer cells via activation of caspases. Active caspase have been shown to target beta-catenin, the hallmark of canonical Wnt signaling, for degradation through caspase-directed cleavage. CWP232291 targets beta-catenin for degradation and thereby inhibits the expression of cell cycle and anti-apoptotic genes such as cyclin D1 and survivin.

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome+1 more

JW Pharmaceutical69 participantsStarted Jul 2011

Houston, Texas, United States • Seattle, Washington, United States • Seoul, South Korea +2 more locations

COMPLETEDNA147 miles

Blood and Marrow Transplant Clinical Research Network

NCT00023530

The purpose of this network is to accelerate research in hematopoietic stem cell transplantation by comparing novel therapies to existing ones.

Bone Marrow TransplantationBlood DiseaseHematopoietic Stem Cell Transplantation+4 more

National Heart, Lung, and Blood Institute (NHLBI)Started Sep 2001

Duarte, California, United States • La Jolla, California, United States • Palo Alto, California, United States +13 more locations

COMPLETEDPhase 3147 miles

Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

NCT00112294

The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than patients treated with Taxane/Carboplatin (T/C) alone. The safety of this treatment will also be studied.

Non-Small-Cell Lung Carcinoma

Eli Lilly and Company755 participantsStarted Dec 2004

Birmingham, Alabama, United States • Mobile, Alabama, United States • Anchorage, Alaska, United States +121 more locations

COMPLETEDPhase 1/2147 miles

Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

NCT00103558

This is an open label, Phase I/II, dose escalation research study of an investigational product called lumiliximab, given with FDA (Food and Drug Administration) approved products fludarabine, cyclophosphamide, and rituximab (FCR). The study duration is 17 visits over 42 months or until your disease progresses and you require additional CLL therapy. The total duration of participation in the study will be approximately 4 years, however your disease status will be followed indefinitely (forever).

Chronic Lymphocytic Leukemia

Biogen31 participantsStarted Mar 2004

Birmingham, Alabama, United States • San Diego, California, United States • Baltimore, Maryland, United States +2 more locations

COMPLETEDPhase 2182 miles

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

NCT01297491

The purpose of this two-stage phase II study is to assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. BKM120 will be investigated in two groups of NSCLC patients according to the histology of the cancer: squamous and non-squamous.

Non-small Cell Lung Cancer

Novartis Pharmaceuticals63 participantsStarted May 2011

Chandler, Arizona, United States • Phoenix, Arizona, United States • Scottsdale, Arizona, United States +89 more locations

COMPLETEDPhase 2182 miles

Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

NCT00112346

The primary purpose of this study is to estimate the number of patients with non-small cell lung cancer whose tumor responds to the treatments given in this study.

Non-Small-Cell Lung Carcinoma

Eli Lilly and Company120 participantsStarted Jan 2005

Mobile, Alabama, United States • Anchorage, Alaska, United States • Bakersfield, California, United States +35 more locations

COMPLETEDNA194 miles

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer

NCT02064829

The purpose of this study is to demonstrate bioequivalence of IG-001 versus nab-paclitaxel in female patients with metastatic or locally recurrent breast cancer. In addition, the study will compare the safety and tolerance of IG-001 and nab-paclitaxel during the bioequivalence 2-period crossover portion of the study. The study will also evaluate the long-term safety of IG-001 over repeated cycles, up to 4 additional cycles of administration.

Metastatic Breast CancerLocally Recurrent Breast Cancer

Sorrento Therapeutics, Inc.111 participantsStarted Mar 2014

Fayetteville, Arkansas, United States • Chattanooga, Tennessee, United States • Memphis, Tennessee, United States +17 more locations

COMPLETEDPhase 2332 miles

Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer

NCT01109524

The purpose of the study is to determine if U.S. manufactured Cetuximab can be safely used for the treatment of Non-Small Cell Lung Cancer in combination with Cisplatin and Vinorelbine.

Lung NeoplasmsCarcinomaCancer of the Lung+1 more

Eli Lilly and Company72 participantsStarted Jul 2010

Casa Grande, Arizona, United States • Beverly Hills, California, United States • Los Angeles, California, United States +19 more locations

COMPLETEDPhase 3353 miles

Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib

NCT00802841

There is no available data on the clinical benefit of dose escalation for patients with suboptimal response to imatinib, and patients may still improve their response with continuation of therapy at the standard dose as shown in the IRIS trial after 5 years of follow-up. However, there is no data yet regarding the potential benefit of using nilotinib in the group of patients with suboptimal response. In this study, the efficacy of nilotinib 400mg BID will be compared to imatinib 600mg QD.

Chronic Myelogenous Leukemia

Novartis Pharmaceuticals191 participantsStarted May 2009

Caba, Buenos Aires, Argentina • Caba, Buenos Aires, Argentina • La Plata, Buenos Aires, Argentina +53 more locations

COMPLETEDPhase 2360 miles

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

NCT00671788

Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

Gynecologic Oncology Group35 participantsStarted Jun 2008

Hartford, Connecticut, United States • New Britain, Connecticut, United States • Sarasota, Florida, United States +17 more locations

TERMINATEDPhase 3403 miles

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00738881

This randomized phase III trial studies pemetrexed disodium to see how well it works compared with erlotinib hydrochloride as second-line therapy in treating patients with non-small cell lung cancer that has spread to other places in the body. Pemetrexed disodium and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether pemetrexed disodium is more effective than erlotinib hydrochloride in treating advanced non-small cell lung cancer.

Recurrent Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung Cancer+1 more

National Cancer Institute (NCI)23 participantsStarted Oct 2008

Scottsdale, Arizona, United States • Fort Smith, Arkansas, United States • Antioch, California, United States +266 more locations

COMPLETEDPhase 2560 miles

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

NCT00769067

This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one of these drugs, and followed for efficacy and tolerance of each.

Non-small Cell Lung Cancer

Pfizer188 participantsStarted Nov 2008

Muscle Shoals, Alabama, United States • Montebello, California, United States • Bridgeport, Connecticut, United States +56 more locations

COMPLETEDPhase 2753 miles

Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

NCT01533181

The purpose of this study is to evaluate how OSI-906 compares to Topotecan in trying to slow down the growth and/or progression of the tumors of participants with relapsed or recurrent Small Cell Lung Cancer. This study also plans to find out what effects, good or bad (side effects), OSI-906 has on participants and or Small Cell Lung Cancer. The study will also investigate if some proteins measured in the blood or tumor and some imaging features obtained from computed tomography (CT) scans can help predict whether OSI-906 or topotecan will be effective against Small Cell Lung Cancer.

Recurrent Small Cell Lung Carcinoma

National Cancer Institute (NCI)44 participantsStarted Feb 2012

Scottsdale, Arizona, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +8 more locations

COMPLETEDPhase 1766 miles

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

NCT01121575

Lung cancer tumors become resistant to the first generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib by changing and increasing the activity of two cell signaling pathways: the cMET pathway and the EGFR pathway. Both resistance mechanisms can occur at the same time, in the same patient and even in the same tumor. This study combines a second generation EGFR inhibitor and a cMET inhibitor to block both these pathways in order to overcome resistance and treat this disease.

Non Small Cell Lung Cancer

Pfizer70 participantsStarted Aug 2010

Aurora, Colorado, United States • Aurora, Colorado, United States • Aurora, Colorado, United States +7 more locations

PreviousPage 56 of 64Next

Other Conditions in Austin

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Lymphoma